Abstract
1042P INSIGHT 003 evaluating feasibility of eftilagimod alpha (soluble LAG-3) combined with first-line chemo-immunotherapy in metastatic non-small cell lung cancer (NSCLC) adenocarcinomas
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have